Skip to main content Skip to section navigation Skip to footer
French

Acasti Pharma Inc.

  • English
  • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Clinical Pipeline
    • GTX-104
    • GTX-102
    • GTX-101
  • Investor Relations
    • Overview
    • News / Events
    • Company Info
    • Financial Results
    • Stock Data
    • Regulatory Filings
    • Governance
  • Newsroom
  • Careers
  • Contact
  • French

Press Releases

Investor Relations

Investor Relations

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Media
    • IR Calendar
    • Email Alerts
    • Grace Merger Conference Call
  • Company Info
    • Overview
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: ACST
    • TSXV: ACST
    • Analyst Coverage
  • Regulatory Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
    • SEDAR
    • Tax Notifications
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News / Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts
  • Grace Merger Conference Call

Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

Aug 2, 2022

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

Jul 27, 2022

Acasti Pharma Announces Annual Grants of Performance Stock Options

Jun 22, 2022

Acasti Pharma Reports Fiscal Year 2022 Operational Results

Jun 21, 2022

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

Jun 16, 2022

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Jun 14, 2022

Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

May 23, 2022

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

May 18, 2022

Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18th

May 16, 2022

Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th

Apr 25, 2022
rss_feed News RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...25
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Acasti Pharma Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap